Lupin was up by 3% at Rs.863 on 14 May after it API (Active Pharmaceutical Ingredients) unit located in Visakhapatnam received establishment inspection report (EIR) from the US Food and Drug Administration (FDA). The inspection of the API facility was conducted by the USFDA in the second week of January 2020. In April, Lupin had informed the stock exchange that FDA had closed its inspection of manufacturing facility in Pithampur in the state of MP. EIR is an indication that there are no serious lapses in the facility. This regulatory resolution is likely to allow Lupin to make a strong comeback in the US market where pricing environment has stabilized and trade-war concerns between US and China could provide an opportunity to India. The post COVID-19 situation is also likely to be more favorable to Indian companies as Indian generics are likely to be seen in positive light now.